Hutchmed announces that it has completed patient enrollment of Phase II registration trial of amdizalisib in patients with relapsed or refractory follicular lymphoma, or FL, a subtype of non-Hodgkin’s lymphoma, or NHL. The last patient was enrolled on February 24.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCM:
- HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
- HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
- HUTCHMED to Announce 2022 Final Results
- Hutchmed Soars on Drug Deal with Takeda
- Hutchmed licenses fruquintinib to Takeda Pharmaceutical for up to $1.13B